2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
29
Hodgkin Disease
20
Central Nervous System Neoplasms
16
Astrocytoma
11
Oligodendroglioma
10
Glioblastoma
9
Brain Neoplasms
9
Gliosarcoma
7
Glioma
6
Recurrence
5
Lymphoma, Non-Hodgkin
4
Neurotoxicity Syndromes
3
Lymphoma, Follicular
3
Lymphoma, Mantle-Cell
2
Lymphoma, AIDS-Related
2
Radiation Injuries
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Optic Nerve Glioma
1
Medulloblastoma
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Intraocular Lymphoma
1
HIV Infections
1
Familial ependymoma
1
Ependymoma
1
Drug-Related Side Effects and Adverse Reactions
1
Burkitt Lymphoma
1
Ataxia Telangiectasia
1
Ataxia
1
Interventions
Rituximab
17
Peripheral Blood Stem Cell Transplantation
15
Cyclophosphamide
15
fludarabine phosphate
12
Whole-Body Irradiation
11
Cyclosporine
10
Mycophenolic Acid
9
Etoposide
9
Methotrexate
8
Filgrastim
8
Lenalidomide
7
Tacrolimus
6
Dexamethasone
6
Busulfan
6
Radiotherapy
5
Melphalan
5
Cytarabine
5
Carboplatin
5
Vorinostat
4
Thiotepa
4
Therapeutics
4
Psychiatric Rehabilitation
4
Bortezomib
4
Antilymphocyte Serum
4
Transplantation
3
Methylprednisolone
3
Irinotecan
3
Granulocyte Colony-Stimulating Factor
3
Flow Cytometry
3
Dasatinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Intraocular Lymphoma
×
Procarbazine
×
Clear all
NCT00074191
2017-04-21
Protocol-A
OHSU Knight Cancer Institute
Phase 2
Completed
1 enrolled